KLK14 as a novel therapeutic target in muscle wasting induced by androgen deprivation therapy
This project aims to determine if the PSA-related protease, KLK14, induces muscle wasting in men on androgen deprivation therapy (ADT) and determine the underlying mechanisms involved in this process.
This study will determine:
-
the expression levels of KLK14 in muscle biopsies from men with prostate cancer, both ADT treatment naive and on ADT;
-
the regulatory response of KLK14 in a human skeletal muscle cell line to androgen stimulation (DHT) and the anti-androgens, bicalutamide and enzalutamide to mimic the clinical ADT setting;
-
the mechanisms of KLK14 mRNA induction and downstream consequences of KLK14 action that drives the skeletal muscle microenvironment remodelling in ADT.
Duration
2016 - 2016
Funding
| Prostate Cancer Foundation of Australia | $99 732 |
